Tuebingen, Germany and Houston, Texas, May 26, 2021 -- Immatics N.V. 
https://www.globenewswire.com/Tracker?data=Fr3Dd4AOlxE10vCHLFVceI36SqfQ0QehremllUDKXupQQFuLSvI1F2YzQY-oZP9rbxHEOufgqiNo-C6HYWLXjQ== 
(NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company 
active in the discovery and development of T cell-redirecting cancer 
immunotherapies, today announced changes to its Board of Directors. 
Christof Hettich, L.L.D., Managing Partner and founding member of the 
dievini Hopp BioTech holding GmbH & Co. KG, has decided to step down 
from Immatics' Board of Directors. He has been a member of Immatics' 
Board of Directors since 2006. Former Immatics Board member Friedrich 
von Bohlen und Halbach, PhD, Managing Partner and co-founder of dievini 
Hopp BioTech Holding GmbH & Co. KG has been nominated to be his 
successor. The election will take place at Immatics' Annual General 
Meeting on June 17, 2021. 
 
   Peter Chambré, Chairman of Immatics' Board of Directors commented: 
"I would like to thank Christof Hettich on behalf of my fellow Board 
members and the Immatics' management team for his tremendous 
contributions to the company for more than 15 years. He has been 
instrumental in the development of Immatics over this period. We would 
be delighted to welcome Friedrich von Bohlen und Halbach back to our 
Board of Directors." 
 
   Dr. Friedrich von Bohlen und Halbach is Managing Partner and co-founder 
of dievini Hopp BioTech Holding GmbH & Co. KG, the company managing the 
life science activities and investments of Dietmar Hopp, co-founder of 
SAP, and his family. Friedrich von Bohlen und Halbach holds a diploma in 
biochemistry from the University of Zurich and a PhD in neurobiology 
from the Swiss Federal Institute of Technology (ETH) in Zurich. He held 
various positions at Fresenius AG, FAG Kugelfischer KGaA and WASAG 
Chemie AG. In 1997 he founded LION bioscience AG whose CEO he was for 
seven years. He is chairman of the Board of Apogenix AG and Novaliq GmbH, 
and board member of CureVac AG, Heidelberg Pharma AG and Co-Chair of the 
Evaluation Board of the Wyss Translational Center Zurich. Friedrich von 
Bohlen und Halbach is also co-founder and Managing Director of Molecular 
Health GmbH. Friedrich von Bohlen und Halbach has been a member of 
Immatics' Board of Directors from 2006 to 2020. 
 
   - END - 
 
   About Immatics 
 
   Immatics combines the discovery of true targets for cancer 
immunotherapies with the development of the right T cell receptors with 
the goal of enabling a robust and specific T cell response against these 
targets. This deep know-how is the foundation for our pipeline of 
Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships 
with global leaders in the pharmaceutical industry. We are committed to 
delivering the power of T cells and to unlocking new avenues for 
patients in their fight against cancer. 
 
   For regular updates about Immatics, visit www.immatics.com. You can also 
follow us on Twitter 
https://www.globenewswire.com/Tracker?data=00CNroZHoO3pwjd_qfbG1bI2ZbieUa2gJJp5d6BB2YOdqR6McXPdYglToQW_q-PKka9DZ1Aux5Ihr3MGBXdW1w== 
and LinkedIn 
https://www.globenewswire.com/Tracker?data=YgvS3cbKLf7l03_fTbBgzJN1Xu-K_lUHcC3PlAqr7GOPyomQWdN3LqWs6o5n0gbOzH-ATiG-P4dc7l0NiwXrdp7PhIbarHOJyL554wkLxQlRJUZByh-19eCJmfdHd9IC 
. 
 
   For more information, please contact: 
 
 
 
 
For media enquiries              Investor Relations Contact 
Jacob Verghese or Stephanie May  John Graziano 
Trophic Communications           Solebury Trout 
Phone: +49 89 2388 7731          Phone: +1 646-378-2942 
immatics@trophic.eu              jgraziano@soleburytrout.com 
 
 
 
 
 
 
 
 
Immatics N.V.             Investor Relations Contact 
Anja Heuer                Jordan Silverstein 
Corporate Communications  Head of Strategy 
Phone: +49 89 540415-606  Phone: +1 281-810-7545 
media@immatics.com        InvestorRelations@immatics.com 
 
 
 
 
   Attachment 
 
 
   -- PDF Version 
      https://ml-eu.globenewswire.com/Resource/Download/6d8a8e08-4b39-484b-ad83-585ee15f3018

(END) Dow Jones Newswires

May 26, 2021 07:00 ET (11:00 GMT)